α-Hydroxylation of ketones: Osmium tetroxide/N-methylmorpholine-N-oxide oxidation of silyl enol ethers
作者:J.P. McCormick、Witold Tomasik、Mark W. Johnson
DOI:10.1016/s0040-4039(01)92501-8
日期:1981.1
Osmium tetroxide/N-methylmorpholine-N-oxide oxidation of silyl enolethers, derived from ketones with either kinetic or thermodynamic regiochemical control, produces α-ketols in good to excellent yields.
Direct α-hydroxylation of ketones using molecular oxygen was accomplished by organic–inorganic hybrid polymers. A newly prepared Cu-piperazine hybrid polymer was tolerant to the basic conditions, and with employment of lithium hydroxide smoothly catalyzed the α-hydroxylation of ketones. In the present catalytic process not only tetralone derivatives, but also acyclic ketones were converted to the α-hydroxy ketones in good yield.
A chemo- and regioselective α-hydroxylationreaction of carbonyl compounds with molecularoxygen as oxidant is reported. The hydroxylation reaction is catalyzed by a dinuclear Pd(II) complex, which functions as an oxygen transfer catalyst, reminiscent of an oxygenase. The development of this oxidation reaction was inspired by discovery and mechanism evaluation of previously unknown Pd(III)-Pd(III)
Iron(<scp>iii</scp>) chloride hexahydrate-promoted selective hydroxylation and chlorination of benzyl ketone derivatives for the construction of hetero-quaternary scaffolds
作者:Tao Chen、Rui Peng、Wenxin Hu、Fu-Min Zhang
DOI:10.1039/c6ob01733a
日期:——
A novel and tunable α-hydroxylation/α-chlorination of benzyl ketone derivatives has been developed for the construction of hetero-quaternary carbon centers by iron(III) chloride hexahydrate mediated selective transformations through the application of different oxidants, especially the crystal water in the catalyst as an OH source is firstly reported in this hydroxylation.
DECALINE-DERIVED COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS
申请人:Odermatt Alex
公开号:US20090062401A1
公开(公告)日:2009-03-05
The present invention relates to compounds having a decaline scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said decaline-derived compounds can be used for prophylaxsis and/or treatment of diabetes mellitus type I, diabetes mellitus type II, tuberculosis and other infectious diseases, proliferative diseases, cancer, neurodegenerative diseases, obesity, cognitive dysfunctions and metabolic syndromes.